Business EconomyPosted at: May 16 2026 9:42PM


Dr. Reddy’s launches generic Semaglutide injection in Canada

Hyderabad, May 16 (UNI) Dr. Reddy’s Laboratories, the Hyderabad-based global pharmaceutical major, on Saturday announced the launch of its generic Semaglutide Injection in Canada.
Dr. Reddy’s is among the first companies to introduce a generic Semaglutide Injection in the Canadian market following the Notice of Compliance (NOC) granted by Health Canada on April 28, 2026.
Canada has become the first G7 nation to grant market authorisation for generic Semaglutide Injection, marking a significant milestone in the global expansion of GLP-1 therapies, the pharmaceutical company said in a release here.
According to the company, the launch reflects Dr. Reddy’s preparedness to ensure rapid patient access following regulatory approval.
In Canada, Dr. Reddy’s Semaglutide Injection is indicated as a once-weekly treatment for adults with Type 2 Diabetes Mellitus to improve glycaemic control alongside diet and exercise.
The medication is supplied as a sterile solution for subcutaneous injection in pre-filled pens and is available in 2 mg/pen and 4 mg/pen strengths. Each pen delivers semaglutide at a concentration of 1.34 mg/ml.
The 2 mg pen is designed to administer 0.25 mg or 0.5 mg doses, while the 4 mg pen delivers 1 mg per injection.
Erez Israeli, Chief Executive Officer of Dr. Reddy’s, said: “We are pleased to launch our generic Semaglutide Injection in Canada within days of receiving Health Canada approval. This milestone highlights our readiness to serve Canadian patients, supported by our deep expertise in complex drug and peptide development.”
“With our well-established presence and strong market access capabilities in Canada, we remain committed to bringing advanced, high-quality and affordable GLP-1 therapies closer to patients,” he added.
The Canada launch follows the company’s recent introduction of the drug in India under the brand name Obeda®.
“As GLP-1 therapies continue to be a key focus area for us, we are actively working to expand access across multiple global markets,” Erez Israeli said.
Semaglutide Injection is intended for adult patients with Type 2 diabetes to improve glycaemic control in combination with diet and exercise, particularly where metformin is unsuitable due to contraindications or intolerance.
The company clarified that Semaglutide has not been studied in combination with short-acting prandial insulin and should not be considered a substitute for insulin.
It is also not indicated for patients with Type 1 diabetes or for the treatment of diabetic ketoacidosis.
UNI KNR RN
Please log in to get detailed story.
Tags: #Dr. Reddy’s launches generic Semaglutide injection in Canada
More News

Govt exempts Ethanol Blended Petrol (EBP) from central excise duties

12 Jun 2026 | 12:21 AM

New Delhi, Jun 11 (UNI) The Government on Thursday exempted Ethanol Blended Petrol (EBP) from applicable central excise duties, an official order said.

see more..

Bajaj Auto Foundation commits Rs 400 Crore through Rupa Rahul Bajaj Scholarship

11 Jun 2026 | 8:50 PM

India's largest scholarship program for women in core engineering
Pune, June 11 (UNI) Bajaj Auto Foundation, the CSR arm of Bajaj Auto Limited, on Thursday announced a landmark commitment of Rs 400 crore over the next decade to empower women engineers through the Rupa Rahul Bajaj Scholarship for Women in Engineering (RRBSWE).

see more..

Indian stock markets end lower amid fresh blows between US and Iran

11 Jun 2026 | 7:26 PM

New Delhi, June 11 (UNI) Indian stock markets on Thursday ended lower in a highly volatile session. Nifty 50 close below the 23,200 mark amid broad-based selling across sectors, and taking fresh cues from the United States (US) fresh attack on Iran.
At close, the Sensex was down 150.63 points or 0.20 percent at 73,832.55, and the Nifty was down 53.35 points or 0.23 percent at 23,161.60.

see more..

Piyush Goyal will visit Switzerland to foster implementation of TEPA

11 Jun 2026 | 6:44 PM

New Delhi, Jun 11 (UNI) Commerce and Industry Minister Piyush Goyal is scheduled to visit Berne, Switzerland, on June 12, where he will meet senior Swiss government officials and leading representatives of the pharmaceutical industry to advance the implementation of the Trade and Economic Partnership Agreement (TEPA) and further deepen economic ties between India and Switzerland.

see more..

Reliance 4IR Realty consortium bags Mumbai slum redevelopment project

11 Jun 2026 | 5:35 PM

Mumbai, June 11 (UNI) A consortium led by Reliance 4IR Realty Development Limited which is a subsidiary of the Mukesh Ambani-led Reliance Industries Ltd (RIL) has emerged as the highest bidder for the cluster redevelopment of the 101-acre Juhu slum corridor, according to official sources.

see more..